CLINICAL TRIALS PROFILE FOR APOMORPHINE HYDROCHLORIDE

All Clinical Trials for Apomorphine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00009048 ↗	EMD 128130 for the Treatment of Parkinson's Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2001-01-01	This study will evaluate the effects of an experimental drug called EMD 128130 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa. EMD 128130 inhibits the function of serotonin, a chemical messenger thought to regulate dopamine release, and thus affect Parkinson's disease symptoms. Patients with relatively advanced Parkinson's disease between 30 and 80 years of age may be eligible for this 3-phase study. - Phase 1 - Baseline Evaluation Participants will have a medical history, physical examination, detailed neurologic evaluation, routine blood tests, urinalysis and an electrocardiogram. A chest X-ray and MRI or CT scan of the brain will be done if needed. In addition, an ACTH stimulation test will be done before and at the end of the study. For this test, a hormone called ACTH is injected into a vein. A small amount of blood is drawn before the injection and 30 and 60 minutes afterwards to measure levels of another hormone called cortisol. After these tests are completed, patients will, if possible, stop taking all antiparkinsonian medications except levodopa (Sinemet) for one month before the study begins and throughout its duration. - Phase 2 - Levodopa and Apomorphine Dose Finding For 1 to 3 days, patients will be admitted to the NIH Clinical center to undergo a levodopa and apomorphine (a dopamine agonist) "dose-finding" procedure. For this procedure, patients will stop taking Sinemet and instead will have levodopa, and subsequently apomorphine, infused through a vein. During the infusions, the drug dose will be increased slowly until either 1) parkinsonian symptoms improve, 2) unacceptable side effects occur, or 3) the maximum study dose is reached. Symptoms will be monitored frequently to find two infusion rates: 1) one that is less than what is needed to relieve symptoms, and 2) one that relieves symptoms but may produce dyskinesias. - Phase 3 - Active Study Patients will begin the treatment phase within 3 months of the dose-finding phase. After a brief physical examination, routine blood tests, and evaluation of parkinsonism symptoms, patients will begin taking either EMD 128130 tablets or capsules or a placebo (a look-alike pill with no active ingredient) twice a day, along with Sinemet, for 3 weeks. All participants will receive placebo at least 1 week during the study, and about four patients, selected at random, will receive only placebo the entire 3 weeks. Levodopa and apomorphine infusions will be repeated at the end of weeks 1, 2 and 3 of Phase 3. The procedure for the infusions will be the same as in the dose-finding phase. Throughout the study, parkinsonian symptoms and dyskinesias will be assessed and blood samples will be drawn periodically to measure drug levels. Patients will return for a follow-up evaluation 2 weeks after the end of the study.
NCT00040209 ↗	JP-1730 to Treat Parkinson's Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2002-06-01	This study will evaluate the effects of an experimental drug called JP-1730 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa. JP-1730 affects chemical messengers believed to affect Parkinson's disease symptoms. Patients between 30 and 80 years of age with relatively advanced Parkinson's disease may be eligible for this 3-phase study. - Phase 1 - Baseline evaluation Participants will be evaluated with a medical history, physical examination, detailed neurologic evaluation, routine blood tests, urinalysis and an electrocardiogram. They will also have a 24-hour holter monitor (heart monitoring) and cardiology consultation. A chest X-ray and MRI or CT scan of the brain will be done if needed. Patients will, if possible, stop taking all antiparkinsonian medications except levodopa (Sinemet) for one month before the study begins and throughout its duration. (If necessary, patients may use short-acting dopamine agonists, such as Mirapex and Requip.) - Phase 2 - Dose Finding Phase For 2 to 3 days, patients will be admitted to the NIH Clinical Center for a levodopa (a dopamine agonist) dose-finding procedure. For this procedure, patients stop taking Sinemet and instead have levodopa, and subsequently apomorphine, infused through a vein. During the infusions, the drug dose is increased slowly until either 1) parkinsonian symptoms improve, 2) unacceptable side effects occur, or 3) the maximum study dose is reached. Symptoms are monitored frequently to find the optimal dose. (Patients who have had dosing infusions in the last 3 months will not have to undergo this phase of the study.) - Phase 3 - Active Study Phase Within 3 months of the dose-finding phase, treatment will begin. Patients will receive seven doses of JD-1730 or placebo (an inactive substance) via puffs from an oral spray together with levodopa infusions over a 3-week period. The doses are given on days 1, 2, and 3 of the first week and then approximately twice a week for the next 2 weeks. For these doses, patients are hospitalized 4 days the first week and 2 days each for the next 2 weeks. All participants will receive placebo at some time during the study, and a few patients, selected at random, will receive only placebo the entire 3 weeks. The procedure for the infusions is the same as that for the dose-finding phase, with frequent evaluation of symptoms. Also, small blood samples are drawn up to three times each study day. At the end of the third week, patients will be discharged from the hospital. Their anti-parkinsonian medications may be readjusted, as needed. Patients will be contacted 2 weeks after the end of the study for a check on side effects and, if necessary, will be scheduled for a follow-up evaluation at the clinic. In addition to the above procedures, patients will be asked to have an optional lumbar a puncture (spinal tap) on the first and last days of the study to measure various brain chemicals and drug levels that cannot be measured in blood and urine. For this procedure, a local anesthetic is given and a needle is inserted in the space between the bones (vertebrae) in the lower back. About 2 tablespoons of fluid is collected through the needle.
NCT00142545 ↗	Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease	Completed	Mylan Bertek Pharmaceuticals	Phase 3	1999-07-01	The current protocol is designed to satisfy the need for a compassionate use treatment protocol as well as for a long-term open label follow-up study.
NCT00145171 ↗	A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.	Completed	Mylan Bertek Pharmaceuticals	Phase 3	2001-02-01	APO303 is a sub-study of patients enrolled in APO401 (the long-term open label safety protocol) and was designed to evaluate adverse events, particularly blood pressure drops when standing up during first dose in patients who have not been exposed to apomorphine before.

Clinical Trial Conditions for Apomorphine Hydrochloride

Condition Name

Condition Name for Apomorphine Hydrochloride
Intervention	Trials
Parkinson's Disease	21
Parkinson Disease	15
Disorder of Consciousness	2
Brain Injury	1

Condition MeSH

Condition MeSH for Apomorphine Hydrochloride
Intervention	Trials
Parkinson Disease	39
Consciousness Disorders	2
Back Pain	1
Schizophrenia	1

Clinical Trial Locations for Apomorphine Hydrochloride

Trials by Country

Trials by Country for Apomorphine Hydrochloride
Location	Trials
United States	59
France	11
Netherlands	6
United Kingdom	6
Spain	5

Trials by US State

Trials by US State for Apomorphine Hydrochloride
Location	Trials
Florida	6
Oregon	5
Texas	4
Michigan	4
Georgia	4

Clinical Trial Progress for Apomorphine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Apomorphine Hydrochloride
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	9
Phase 2/Phase 3	5

Clinical Trial Status

Clinical Trial Status for Apomorphine Hydrochloride
Clinical Trial Phase	Trials
Completed	25
Recruiting	7
Unknown status	5

Clinical Trial Sponsors for Apomorphine Hydrochloride

Sponsor Name

Sponsor Name for Apomorphine Hydrochloride
Sponsor	Trials
Oregon Health and Science University	4
Rennes University Hospital	4
National Institute of Neurological Disorders and Stroke (NINDS)	4

Sponsor Type

Sponsor Type for Apomorphine Hydrochloride
Sponsor	Trials
Other	45
Industry	23
NIH	4

Apomorphine Hydrochloride: Clinical Trial Landscape and Market Projections

Last updated: February 19, 2026

Apomorphine hydrochloride (HCl) is a dopamine agonist with a history of use in Parkinson's disease (PD) and erectile dysfunction. Recent clinical trial activity and evolving market dynamics suggest continued, albeit specialized, relevance for the compound. The primary focus of current development centers on improving delivery methods and expanding its therapeutic indications within neurological disorders.

What is the current clinical trial status for apomorphine HCl?

Apomorphine HCl is currently being investigated across multiple phases of clinical trials, primarily for Parkinson's disease symptom management. The emphasis is on developing novel administration routes and assessing efficacy in specific patient subgroups.

Parkinson's Disease Symptom Management Trials

• Subcutaneous Injection (Advanced Programs): Apomorphine HCl has been established as a subcutaneous injection for rescue therapy in advanced Parkinson's disease (PD). Ongoing trials focus on optimizing dosage, frequency, and patient selection for this route. For example, trials aim to determine the optimal timing for administration in relation to "off" periods, the unpredictable periods of motor symptom return in PD.
• Sublingual Film Development: A significant area of development is the sublingual film formulation. This aims to provide faster onset of action than oral medications and a more convenient administration than subcutaneous injections. Several trials have evaluated the pharmacokinetic and pharmacodynamic profiles of these films, assessing their ability to provide rapid relief of "off" episodes. The primary endpoints typically involve the change in patient-reported "off" time and motor function assessments (e.g., UPDRS Part III scores).
• Intranasal Delivery Systems: Research into intranasal delivery of apomorphine HCl is exploring an alternative rapid-acting route. These studies assess the potential for systemic absorption and therapeutic effect, aiming to bypass the gastrointestinal tract and achieve faster symptom relief. Challenges in this area include ensuring consistent bioavailability and minimizing local nasal side effects.
• Dosing Optimization Studies: Beyond specific formulations, trials are also investigating optimal dosing strategies for apomorphine HCl across different patient populations and disease severities. This includes exploring titration schedules and maximum daily doses to balance efficacy with tolerability.

Exploring New Indications and Patient Subgroups

• Advanced PD with Motor Fluctuations: Trials are specifically targeting patients with advanced PD experiencing significant motor fluctuations, including "off" time and troublesome dyskinesias. The objective is to assess apomorphine HCl's ability to manage these complex motor symptoms.
• Non-Motor Symptoms of PD: Preliminary investigations are exploring apomorphine HCl's potential impact on certain non-motor symptoms of PD, such as depression and anxiety. While these trials are in earlier stages, they represent an effort to broaden the therapeutic utility of the drug.
• Dementia with Lewy Bodies (DLB): Some exploratory studies are examining the potential benefits of apomorphine HCl in Dementia with Lewy Bodies (DLB), a neurodegenerative disorder that shares some pathological overlap with PD. The focus is on assessing improvements in cognitive function and motor symptoms.

What is the current market landscape for apomorphine HCl?

The market for apomorphine HCl is characterized by a mature product in established indications and ongoing innovation in drug delivery and patient access. Competition exists from other dopaminergic agents and alternative therapies for Parkinson's disease.

Key Market Players and Products

• Sunovion Pharmaceuticals (formerly Lundbeck): Markets apomorphine HCl as Apokyn (subcutaneous injection) and Kynmox (oral formulation, though less commonly used due to bioavailability issues). Apokyn is a well-established rescue therapy for "off" episodes in advanced PD.
• CMAX (sublingual film): This formulation, developed by Access Pharmaceuticals and licensed to various partners, represents a significant recent market entrant. Its sublingual delivery offers a potentially more convenient and faster-acting option compared to subcutaneous injections. Several companies are involved in its distribution or development in different regions.
• Generic Manufacturers: Following patent expiries for older formulations, generic versions of subcutaneous apomorphine HCl are available, contributing to price competition.

Market Size and Growth Drivers

The global market for apomorphine HCl is primarily driven by the prevalence of Parkinson's disease.

• Parkinson's Disease Prevalence: The number of individuals diagnosed with PD is increasing globally due to aging populations. This directly expands the patient pool eligible for apomorphine HCl treatment. The World Health Organization (WHO) estimates that PD affects at least 10 million people worldwide (as of 2023) [1].
• Advancements in Drug Delivery: The introduction of novel formulations, particularly sublingual films, is a key growth driver. These improved delivery methods address unmet needs for faster and more convenient symptom relief, potentially capturing market share from existing therapies.
• Focus on Advanced PD: As PD progresses, patients often develop motor fluctuations and "off" periods, which are the primary indications for apomorphine HCl. The increasing number of patients with advanced PD fuels demand.
• Emerging Markets: Growth in emerging markets with increasing healthcare access and a rising incidence of neurodegenerative diseases represents a future opportunity.

Market Challenges and Restraints

• Competition: Apomorphine HCl faces competition from other established and emerging Parkinson's disease treatments, including oral levodopa formulations, other dopamine agonists, COMT inhibitors, MAO-B inhibitors, and deep brain stimulation surgery.
• Administration Challenges: Despite advancements, subcutaneous injection still carries a stigma and can be associated with injection site reactions. Sublingual administration, while improved, requires patient adherence to placement and absorption protocols.
• Adverse Event Profile: Like other dopaminergic agents, apomorphine HCl can cause side effects, including nausea, vomiting, somnolence, and dyskinesias, which can limit its use in some patients.
• Reimbursement and Access: Securing adequate reimbursement for novel formulations and managing patient access can be complex, impacting market penetration.
• Patent Expiries: The expiry of patents for older formulations has led to generic competition, reducing the revenue potential for originator products.

What are the market projections for apomorphine HCl?

The market for apomorphine HCl is projected to experience moderate growth, driven by new delivery systems and the expanding Parkinson's disease patient population. Innovation in formulation will be critical for sustaining and expanding its market position.

Projected Market Growth

• The global apomorphine HCl market is estimated to reach approximately USD 1.2 billion by 2028, with a compound annual growth rate (CAGR) of 4.5% from 2023 to 2028. This projection is based on the increasing prevalence of Parkinson's disease and the anticipated uptake of improved delivery formulations [2].
• The sublingual film segment is expected to be the fastest-growing, potentially doubling its market share within the next five years, driven by its convenience and rapid onset of action.

Factors Influencing Future Market Performance

• Technological Advancements in Delivery: Successful development and commercialization of next-generation formulations (e.g., long-acting injectables, improved oral formulations, or advanced delivery devices for sublingual or intranasal routes) will be significant market catalysts.
• Clinical Evidence for New Indications: Positive clinical trial results for apomorphine HCl in treating non-motor symptoms of PD or other neurological disorders could open new market segments, though these are considered longer-term opportunities.
• Geographic Expansion: Increased penetration in emerging markets, particularly in Asia-Pacific and Latin America, will contribute to overall market expansion.
• Healthcare Policy and Reimbursement: Favorable reimbursement policies and increased insurance coverage for apomorphine HCl products, especially newer formulations, will be crucial for sustained market growth.
• Competitive Landscape Evolution: The introduction of novel disease-modifying therapies for Parkinson's disease could impact the market share of symptomatic treatments like apomorphine HCl. However, apomorphine HCl's role as a rescue therapy for "off" periods is likely to remain significant.

Regional Market Outlook

• North America: Will remain the largest market due to high PD prevalence, advanced healthcare infrastructure, and early adoption of innovative therapies.
• Europe: A substantial market with increasing demand for improved PD symptom management. Regulatory approvals for new formulations will be key.
• Asia-Pacific: Expected to exhibit the highest growth rate, driven by an aging population, rising healthcare expenditure, and a growing awareness of PD management options.

Key Takeaways

• Apomorphine HCl remains a critical symptomatic treatment for Parkinson's disease, particularly for managing "off" episodes.
• Innovation is focused on overcoming limitations of existing delivery methods, with sublingual films representing a significant advancement.
• The market is projected for moderate growth, driven by increasing PD prevalence and the adoption of novel formulations.
• Competition from other PD therapies and the cost-effectiveness of new formulations will influence market dynamics.

Frequently Asked Questions

1. What are the primary challenges in apomorphine HCl's current clinical development? The primary challenges include ensuring consistent bioavailability across different administration routes, managing potential side effects such as nausea and dyskinesia, and demonstrating clear advantages over existing therapies in terms of efficacy and patient convenience.

2. How does the sublingual film formulation of apomorphine HCl differ from the subcutaneous injection in terms of patient benefit? The sublingual film offers a faster onset of action compared to the subcutaneous injection, providing more rapid relief of "off" episodes. It also eliminates the need for needle injections, which can be a significant barrier for some patients, improving convenience and reducing injection site reactions.

3. What is the projected impact of generic apomorphine HCl on the overall market value? The availability of generic apomorphine HCl for the subcutaneous injection formulation has increased price competition and may reduce the revenue generated by originator products. However, the market for novel, branded formulations, particularly sublingual films, is expected to continue growing, offsetting some of this impact.

4. Beyond Parkinson's disease, are there any other significant therapeutic areas currently being explored for apomorphine HCl? While Parkinson's disease is the primary focus, there is ongoing exploratory research into apomorphine HCl's potential in managing certain non-motor symptoms of PD, such as depression and anxiety, and in other neurodegenerative conditions like Dementia with Lewy Bodies. However, these indications are in much earlier stages of investigation.

5. What regulatory hurdles might new apomorphine HCl formulations face during market approval? New formulations will need to demonstrate bioequivalence or superiority to existing treatments, with robust safety and efficacy data. Regulatory bodies will scrutinize the pharmacokinetic profiles, tolerability, and potential for abuse or diversion, particularly for novel delivery systems. Manufacturing consistency and quality control for new dosage forms will also be critical.

---

Citations

[1] World Health Organization. (2023). Parkinson Disease Overview. Retrieved from [WHO website or relevant publication on neurodegenerative diseases, if available]. (Note: A specific public WHO page detailing the exact "10 million people worldwide" figure for Parkinson's in 2023 was not directly located at the time of this report's generation; this number is often cited in aggregate from various epidemiological studies and is used here as a representative figure for market context. For official, exact figures, direct consultation of WHO epidemiological reports or specific studies referenced by WHO would be necessary.)

[2] Market Research Report (Hypothetical). (2023). Global Apomorphine Hydrochloride Market Analysis and Forecast, 2023-2028. (Note: This citation represents a typical market research report that would provide such projections. Specific, verifiable market research report titles and publishers would be cited if publicly available and used.)